XOMA Corp
Research XOMA Corp (XOMA) on Bullrun: market cap USD 503.77M, P/E 25.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXOMA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 503.77M
- P/E25.6
- Financial periodQ1 2026
- RevenueUSD 310.00K
- Net incomeUSD 33.81M
- Free cash flow-USD 13.93M
Valuation Snapshot
latest market cap is USD 503.77M; P/E is 25.6.
Peer valuation comparison
Latest P/E is 25.57x versus a Healthcare sector median of 24.46x (4.5% above).
Latest P/E is 25.57x versus a United States median of 24.87x (2.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 10.35M | USD 31.71M | -USD 17.85M | n/a | 1.46 | USD 82.91M | USD 108.98M | USD 83.94M |
| FY2024 | USD 6.65M | -USD 13.82M | -USD 13.77M | n/a | -1.65 | USD 101.65M | USD 118.27M | USD 61.90M |
| FY2023 | USD 2.65M | -USD 40.83M | -USD 18.18M | n/a | -4.04 | USD 153.29M | USD 124.06M | USD 88.72M |
| FY2022 | USD 4.15M | -USD 17.10M | -USD 28.13M | n/a | -1.98 | USD 57.83M | USD 0 | USD 124.01M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-07-21 | USD 503.77M | 25.6 | n/a | n/a |
| 2025 | 2025-12-31 | USD 315.33M | 18.3 | n/a | n/a |
| 2024 | 2024-12-31 | USD 314.11M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 212.52M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 210.69M | 24.5 | n/a | n/a |
| 2021 | 2021-12-31 | USD 235.92M | 37.2 | n/a | n/a |
About XOMA Corp
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is XOMA Corp's market cap?
XOMA Corp's market capitalization is USD 503.77M.
What is XOMA Corp's P/E ratio?
XOMA Corp's price-to-earnings (P/E) ratio is 25.6.
What does XOMA Corp do?
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets.